Every 8-K that ClearPoint Neuro, Inc. (CLPT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CLPT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CLPT filings page.
ClearPoint Neuro reported second quarter 2026 revenue of $10.9 million, up 18% from $9.2 million, driven by strong growth in neurosurgery navigation and therapy, which rose 62% to $5.6 million, and capital equipment and software, up 24% to $1.3 million. Biologics and drug delivery revenue declined 15% to $4.0 million as large prior-year trial-initiation orders did not repeat, though preclinical service revenue grew. Gross margin improved to 62%.
Operating expenses increased to $17.0 million, reflecting the IRRAflow acquisition and expansion of clinical and sales teams, contributing to an operating loss and a basic and diluted net loss per share of $0.38 versus $0.21 a year earlier. Cash and cash equivalents were $29.4 million at June 30, 2026, down from $45.9 million at year-end, mainly due to $15.0 million used in operating activities and $2.0 million of tax payments related to equity awards. Management now expects 2026 revenue between $48.0 million and $52.0 million.
The company highlighted multiple biopharma partners receiving positive FDA feedback on potential BLA submissions and expects 10–15 clinical trials using its technology to be enrolling in the next 18 months, with roughly 10 data readouts. ClearPoint took possession of its ClearPoint Advanced Laboratories facility, signed initial preclinical statements of work including its first GLP study, and announced a 10-year focused ultrasound drug-delivery partnership with the SONOCARE Lab in South Korea, while advancing its robotic platform and Harmony 1.0 software to expand capacity ahead of potential commercial cell and gene therapy launches around 2027.
ClearPoint Neuro, Inc. held its annual stockholder meeting on May 20, 2026. Stockholders approved the Seventh Amended and Restated 2013 Incentive Compensation Plan, which had previously been adopted by the board subject to stockholder approval, and the full text was filed as an exhibit.
All director nominees were elected to serve until the 2027 annual meeting, each receiving over 9.6 million votes in favor, with additional broker non-votes recorded. Stockholders also ratified Cherry Bekaert LLP as independent auditor for the fiscal year ending December 31, 2026, and gave advisory approval to executive compensation.
Following the meeting, the board set new committee memberships for the audit, compensation, and corporate governance and nominating committees, determining that all members are independent under Nasdaq rules. The board also confirmed R. John Fletcher as Chairman of the Board.
ClearPoint Neuro reported first-quarter 2026 revenue of $12.1 million, up 43% from $8.5 million a year earlier, driven by IRRAflow contributions and strong device demand. Organic revenue grew 16%, with organic devices up 25%, and gross margin improved to 64% from 60%.
Neurosurgery navigation, therapy and access revenue rose 80% to $5.9 million, while capital equipment and software revenue climbed 177% to $1.4 million. Operating expenses increased 44% to $16.2 million, reflecting the IRRAS acquisition and higher personnel and occupancy costs, resulting in a net loss of $9.6 million (–$0.32 per share).
The company ended March 31, 2026 with $35.6 million in cash and cash equivalents, down from $45.9 million at year-end, after using $8.0 million in cash for operating activities and $2.0 million for taxes on equity awards. ClearPoint issued a 2026 revenue outlook of $52.0–$56.0 million and highlighted integration of the IRRAflow portfolio, more than 60 active biopharma partners, new FDA clearance for the Velocity Alpha MR High Speed Surgical Drill System, a Health Canada license for its navigation system, and its first commercial drug delivery case in Asia-Pacific.
ClearPoint Neuro reported strong top-line growth for 2025 while remaining loss-making and investing heavily for future expansion. Total revenue rose to $37.0 million from $31.4 million, an 18% increase, with fourth-quarter revenue up to $10.4 million from $7.8 million, or 34% growth.
Biologics and drug delivery revenue grew 10% to $19.0 million, and neurosurgery navigation and therapy revenue rose 44% to $14.8 million, while capital equipment and software declined 18% to $3.1 million. Gross margin held at 61%, but operating expenses increased 21% to $46.9 million, driving a wider net loss of $25.5 million versus $18.9 million.
The company completed the IRRAS Holdings acquisition, added access to an extra $20.0 million under its Oberland Capital note facility, and ended 2025 with $45.9 million in cash and cash equivalents, up from $20.1 million. For 2026, ClearPoint Neuro projects revenue between $52.0 million and $56.0 million.
ClearPoint Neuro filed an amended current report to add detailed financial information for its acquisition of IRRAS Holdings, Inc. The 8-K/A supplies IRRAS’s audited 2024 financial statements, unaudited 2025 interim results, and unaudited pro forma combined financials showing how the two businesses would look if reported together.
The company emphasizes that these pro forma figures are for informational purposes only and do not represent actual historical results or forecasts of future performance after the acquisition.
ClearPoint Neuro, Inc. furnished an update on its recent performance by disclosing that it has issued a press release with preliminary, unaudited financial results for the fourth quarter ended December 31, 2025. The company used a current report to make investors aware of this earnings-related press release, which is included as an exhibit. The preliminary figures are described only in the press release itself, which is referenced but not detailed here.
ClearPoint Neuro, Inc. (CLPT) completed its acquisition of IRRAS Holdings, Inc. through a two-step merger structure, making IRRAS a wholly owned subsidiary. The company paid $5,000,000 in cash and issued 1,325,000 shares of its common stock as closing consideration to IRRAS stockholders, with additional earnout payments over three one-year periods equal to 25% of net sales of certain IRRAS products above agreed thresholds. The stock portion of the deal was issued in a private transaction relying on exemptions under Section 4(a)(2), Regulation D and Regulation S. Under the merger agreement, some shares are held back for working capital and indemnification adjustments, and ClearPoint agreed to file a registration statement within 30 days to allow resale of the merger shares.
ClearPoint Neuro (CLPT) furnished an 8-K announcing it issued a press release with financial results for the third fiscal quarter ended September 30, 2025, and posted an updated investor presentation.
The press release is provided as Exhibit 99.1 and the investor presentation as Exhibit 99.2. The company noted these materials are being furnished, not filed, and are not incorporated by reference except as expressly set forth in future filings.
ClearPoint Neuro entered into a definitive agreement to acquire IRRAS Holdings, Inc. via a two-step merger. At closing, the consideration will be $5,000,000 in cash and 1,325,000 shares of ClearPoint common stock, with additional earnouts over three one‑year periods equal to 25% of net sales of certain IRRAS products above specified thresholds.
The deal is subject to multiple closing conditions, including the squeeze‑out of minority shareholders of IRRAS AB, delisting of IRRAS AB from NASDAQ Stockholm, customary accuracy and performance conditions, and IRRAS stockholder approval. Either party may terminate if conditions are not met by December 31, 2025. ClearPoint agreed to file a registration statement covering the resale of the merger shares within 30 days after closing.